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As platelet activation is an irreversible and potentially harmful event,platelet stimulatory signaling must be tightly regulated to ensure thefiltering-out of inconsequential fluctuations of agonist concentra-
tions in the vascular milieu. Herein, we show that platelet activation via G
protein-coupled receptors is gradient-dependent, i.e., determined not only
by agonist concentrations per se but also by how rapidly concentrations
change over time. We demonstrate that gradient-dependent inhibition is a
common feature of all major platelet stimulatory G protein-coupled recep-
tors, while platelet activation via the non-G protein-coupled receptor glyco-
protein VI is strictly concentration-dependent. By systematically character-
izing the effects of variations in temporal agonist concentration gradients
on different aspects of platelet activation, we demonstrate that gradient-
dependent inhibition of protease-activated receptors exhibits different
kinetics, with platelet activation occurring at lower agonist gradients for
protease-activated receptor 4 than for protease-activated receptor 1, but
shares a characteristic bimodal effect distribution, as gradient-dependent
inhibition increases over a narrow range of gradients, below which aggre-
gation and granule secretion is effectively shut off. In contrast, the effects of
gradient-dependent inhibition on platelet activation via adenosine diphos-
phate and thromboxane receptors increase incrementally over a large range
of gradients. Furthermore, depending on the affected activation pathway,
gradient-dependent inhibition results in different degrees of refractoriness
to subsequent autologous agonist stimulation. Mechanistically, our study
identifies an important role for the cyclic adenosine monophosphate-
dependent pathway in gradient-dependent inhibition. Together, our find-
ings suggest that gradient-dependent inhibition may represent a new gen-
eral mechanism for hemostatic regulation in platelets.
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ABSTRACT
Introduction
In platelets, G protein-coupled receptors (GPCR) mediate activation in response
to stimulation with multiple important soluble agonists, including thrombin,
adenosine diphosphate (ADP) and thromboxane A2.1 These signaling events are
critical for triggering platelet hemostatic activities such as adhesion,2 granule exo-
cytosis, aggregation, procoagulant activity and clot retraction. Hence, they must be
tightly regulated to ensure efficient hemostasis while concurrently avoiding undue
activation, which could potentially lead to excessive clot growth and thus throm-
bosis, vessel occlusion or embolization. The importance of platelet GPCR in the
pathophysiology of arterial thrombosis is demonstrated by the thrombo-protective
effects of inhibitory drugs targeting GPCR-mediated pathways, such as clopido-
grel, prasugrel, ticagrelor (ADP-receptor P2Y12), aspirin (thromboxane synthesis),
and vorapaxar (thrombin receptor PAR1).
Vascular damage is associated with a localized rapid
increase in the concentrations of soluble agonists acting on
platelet stimulatory GPCR. By contrast, concentrations of
such agonists outside the core of a forming hemostatic
plug change slowly due to dilution, mechanically restrict-
ed diffusion and agonist degradation.3 Recent studies of
intra-thrombus architecture have shown that spatial dif-
ferences in thrombus porosity result in distinct diffusion
rates of solutes,4 leading to heterogeneous concentration
gradients of soluble agonists in different regions inside and
outside a developing thrombus. In pathological conditions
that affect thrombus consolidation and contraction, diffu-
sion of soluble agonists to regions outside the thrombus
core is increased,5 resulting in altered spatial and temporal
distributions of agonists.
In this study, we hypothesized the presence of a gradi-
ent-dependent gating mechanism for platelet activation by
soluble agonists. Gradient-sensing mechanisms are used
in other cell types to regulate dynamic and complex cellu-
lar processes such as chemotaxis,6,7 and can be predicted to
enhance the information processing ability of cells in rela-
tion to changes in the ambient stimulation level.8,9 For
platelets, gradient-sensing could hypothetically enable
dynamic modification of hemostatic responses according
to the type of precipitating event and the relative position
of a platelet in a developing thrombus. Gradient-depen-
dent activation could ensure a robust activation response
under conditions of rapidly increasing agonist concentra-
tions, such as those encountered when a platelet is recruit-
ed from the blood stream to the core regions of a hemo-
static plug. At the other end of the spectrum, gradient-
dependent activation could also provide a mechanism for
ensuring relative inertia in the face of a slow rise of agonist
concentrations, as exemplified by platelets attaching to
the peripheral shell regions of a consolidating thrombus.10
Such a mechanism could conceivably be of particular
importance for regulating the platelet response to throm-
bin stimulation via the protease-activated receptors (PAR1
and PAR4), since one thrombin molecule is capable of irre-
versibly activating an indeterminate number of PAR recep-
tors by enzymatic receptor cleavage. Gradient-dependent
modulation of PAR signaling could thus constitute a previ-
ously unidentified mechanism for equilibrating a signaling
machinery otherwise inherently tilted towards unchecked
platelet activation.
To test our hypothesis, we used novel instrumental
setups to continuously monitor the platelet response to
temporal agonist gradients (Online Supplementary Figure
S1), enabling us to verify the presence of a mechanism for
gradient-dependent inhibition (GDI) of platelet activation
involving activation of cyclic adenosine monophosphate
(cAMP)-dependent signaling mechanisms.
Methods
Blood collection and sample preparation
Whole blood from healthy adult volunteers was collected into
tubes containing hirudin, sodium citrate or acid-citrate-dextrose as
per the local Ethics Committee of Linköping University Hospital
and platelet-rich plasma or washed platelets were prepared using
standard procedures as described in the Online Supplement.
Light transmission aggregometry
Platelet aggregation was measured by light transmission
aggregometry using a Chronolog Corporation model 490-X,
Haverton, USA aggregometer. A pump controlled agonist infu-
sion system (Online Supplementary Figure S1) was developed to
generate constant temporal agonist concentration gradients and
allow for continuous monitoring of platelet aggregation. In this
system, 1 mL disposable plastic syringes were used in the
syringe pumps and connected by fine tubing, of which the other
end was directly immersed (~3 mm) into the platelet-rich plas-
ma in the aggregometer cuvette via a custom-made cuvette
adapter. A Matlab (MathWorks, Natick, USA) program was cre-
ated in-house for controlling infusion rates and agonist loading
(Online Supplementary Figure S1D). Predefined algorithms were
followed for the parameters in the aggregometry experiments
(Figures 1A, 3A and Online Supplementary Figure S2A) to avoid the
potential for bias associated with the ad hoc experimental design.
Based on that, aggregation was measured after infusing the same
volume and concentration of agonists for 2, 40, 80, 160, 320, 640
or 1,280 s. The details of the experimental conditions, including
the use of various inhibitors and the stability of all the agonists
used in the study under experimental conditions, are described
in the Online Supplement.
Flow cytometry
The effect of agonist gradients on platelet a-granule release
was assessed by taking aliquots from samples identical to those
used in the aggregometry experiments except for the inclusion
of a step in which samples were pre-incubated with 1 μM
tirofiban for 10 min at room temperature to prevent aggregation.
Samples were collected 1 min after completion of agonist infu-
sion, labeled and analyzed by flow cytometry as described in the
Online Supplement.
Western blotting
Levels of total serine phosphorylation, total and phosphory-
lated VASP (at S-157) or total and phosphorylated AKT (at S-473)
were assessed by western blotting using standard procedures as
described in the Online Supplement.
Fluorescence microscopy
Resting platelets, platelets activated by PAR1 activating pep-
tide (PAR1-AP) and platelets with induced GDI were visualized
by fluorescence microscopy after staining F-actin according to
the manufacturer’s protocol, as described in the Online
Supplement.
Electron microscopy
Transmission electron microscopy was used to visualize sub-
cellular differences between resting, activated platelets and
platelets with induced GDI, as described in the Online
Supplement.
Results 
A gradient-dependent mechanism modulates G 
protein-coupled receptor-mediated platelet activation
The minimal agonist concentration (Cagg) required to
induce strong aggregation (>65%) in all samples (n≥5)
with an infusion time of 2 s was determined (Table 1)
using the algorithm shown in Online Supplementary Figure
S2A (results in Online Supplementary Figure S2B). To verify
the presence of GDI, we then sought to identify the high-
est concentration gradient (ΔCnres) at which no significant
aggregation (<25%) was observed in ≥75% of samples at
a final agonist concentration of Cagg (algorithm in Figure
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1A). Raw curves from the aggregometry experiments used
to define ΔCnres for the different agonists are shown in
Figure 1B and a color map to aid visual interpretation is
provided in Figure 1C. Our results clearly show that
platelet GPCR-mediated responses to PAR1-AP, PAR4-AP
and ADP exhibit gradient dependence. In contrast, gradi-
ent dependence was not observed for the cross-linked col-
lagen-related peptide (CRP-XL), (Figure 1B-D) or for the
inhibitory signaling elicited by stimulation of the prosta-
cyclin receptor (IP) with PGE1 (Online Supplementary Figure
S3), even when using the longest infusion time of 1,280 s.
For the TPa receptor agonist (U46619), large inter-individ-
ual differences in platelet reactivity to different agonist
gradients precluded any general conclusions. Interestingly,
lowering the infusion rates produced qualitatively distinct
inhibitory effects on aggregation for different agonists. For
ADP, GDI produced incremental decreases in aggregation
over a wide range of infusion times. In contrast, for the
PAR peptides, GDI increased dramatically over a narrow
range of infusion times, with infusion times above a cer-
A.S. Macwan et al.
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Figure 1. Gradient-dependent inhibition of G protein-coupled receptor-mediated platelet aggregation. To experimentally verify the presence of a gradient-dependent
mechanism modulating platelet aggregation, light transmission aggregometry was conducted according to the experimental algorithm in (A), where the identification
of an agonist gradient (ΔCnres) at which no significant aggregation (<25%) occurred despite reaching an agonist concentration sufficient to elicit strong aggregation
when using a 2 s agonist infusion time, was interpreted as proof of the presence of gradient-dependent inhibition. (B) Aggregation raw curves obtained using the
algorithm in (A) for different agonists and gradients, n≥5. (C) Heat map showing mean maximum aggregation for all experiments in (B). (D) Logistic regression was
performed to calculate the infusion time at which >50% of samples could be expected to give <25% aggregation for the respective agonists (t50). Dots represent the
outcome of individual experiments for which data have been dichotomized so that >25% aggregation is denoted as “aggregation” and <25% aggregation is denoted
as “no aggregation”. Confidence bands represent 95% confidence intervals.
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tain agonist and individual-specific threshold resulting in a
complete inhibition of aggregation (Figure 1B,C). For
example, in the case of PAR4-AP, the maximum aggrega-
tion observed was either below 20% or above 60%, but
not in between; in other words, the aggregation response
was “on or off”. To account for this phenomenon, we used
logistic regression to model the effects of GDI for each
agonist, using a threshold of 25% reduction in absorbance
to discriminate between “aggregation” and “no aggrega-
tion” (Figure 1D, Table 1). In this model, we defined the
measure t50 as the minimal infusion time at which ≥50%
of the samples ceased to aggregate. Aggregation induced
by PAR1-AP was most sensitive to GDI, with a t50 of 151
s, whereas the effects of GDI on the aggregatory response
to stimulation with PAR4-AP required significantly longer
infusion times, with a t50 of 607 s.
To investigate the impact of GDI on thrombin-induced
platelet activation, we performed infusion experiments
with thrombin (final concentration 1 U/mL) in citrated
platelet-rich plasma treated with Gly-Pro-Arg-Pro (GPRP)
to prevent fibrin polymerization (Figure 2A,B). Our results
show that GDI has dramatic effects on the platelet aggre-
gatory response to thrombin stimulation even at short
infusion times, with almost complete inhibition at an infu-
sion time of 80 s. The difference in the effect distribution
of GDI between PAR and ADP receptors is illustrated by a
comparison of the representative curves for thrombin
(Figure 2A) with those for ADP (Figure 2C), showing a
bimodal effect distribution for thrombin whereas GDI
increases incrementally over a large range of gradients for
ADP. Results obtained with thrombin were further con-
firmed by simultaneous infusion of PAR1-AP and PAR4-
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Figure 2. Characterization of gradient-dependent inhibition using thrombin, ADP, paracrine signaling inhibition and α-granule secretion. (A,B) To quantify the effects
of gradient-dependent inhibition (GDI) on platelet aggregation induced by thrombin, light transmission aggregometry was performed on platelet-rich plasma pre-incu-
bated with 4 mM GPRP to prevent fibrin polymerization. Thrombin (1 U/mL) was added with different infusion times as indicated, n≥3. (C) Platelet aggregation
induced by ADP added with different infusion times as indicated. (D-F) The role of paracrine stimulation in GDI of PAR signaling was quantified by performing light
transmission aggregometry on platelet-rich plasma in the presence of P2Y1, P2Y12 and thromboxane synthesis inhibitors (MRS2179, cangrelor and ASA), using the
agonists PAR1-AP (30 μM) and PAR4-AP (300 μM), n≥3 (G). The effects of GDI on a-granule release were analyzed by measuring the percentage of platelets positive
for CD62P (P-selectin), using flow cytometry, at different infusion rates, n ≥5. Data represent mean ± standard deviation. *P<0.05, **P<0.01 and ***P<0.001
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AP to mimic the composite stimulus of PAR obtained with
thrombin (Online Supplementary Figure S4).
The secondary mediators ADP and thromboxane A2 play
an important role in amplifying stimulatory signaling from
PAR receptors and have previously been shown to be sus-
ceptible to desensitization.11-13 To assess how ADP and
thromboxane A2 affect GDI of PAR receptor-mediated
platelet activation, we performed additional experiments in
which PAR-APs were infused in the presence of inhibitors
of P2Y1, P2Y12, and thromboxane synthesis. Surprisingly, the
effects of GDI on PAR receptor-mediated platelet activation
was enhanced in the absence of paracrine signaling, as the
t50 was reduced from 151 s to 77 s and from 607 to 320 s for
PAR1 and PAR4, respectively (Figure 2D-F).
Gradient-dependent inhibition of platelet 
alpha-granule exocytosis and intracellular 
calcium mobilization
To test whether GDI was a general feature of stimulato-
ry GPCR signaling and not restricted to platelet aggrega-
tion, we investigated the gradient-dependent effects on a-
granule exocytosis, measured by flow cytometry as P-
selectin exposure (Fig. 2G). Using the highest concentra-
tion gradient with an infusion time of 2 s, all agonists,
except ADP, induced strong P-selectin expression (>80%),
in accordance with in vitro observations by other groups
showing that stimulation with ADP is not sufficient to
evoke a robust paracrine response in platelets.14-16
Interestingly, a striking difference was observed in the
effects of GDI between PAR4 and PAR1-mediated activa-
tion, as PAR4-AP continued to produce a virtually intact P-
selectin exposure (>90 %) until the gradient was lowered
to an infusion time of 640 s, whereas GDI of PAR1-AP-
induced P-selectin exposure was evident already when
using the 80 s infusion time (Figure 2G). In line with the
results from the aggregometry experiments described
above, glycoprotein VI (GPVI)-mediated platelet activa-
tion by CRP-XL showed no signs of GDI, producing a
high P-selectin exposure that remained >80% even at the
lowest concentration gradient tested (infusion time 1,280
s). Although the large inter-individual differences
observed for U46619 in the aggregometry experiments
were still evident to some extent, the effects of GDI on a-
granule release were evident at longer infusion times, i.e.,
640 s and 1,280 s.
While the effects of GDI on GPCR signaling were
prominent also when measuring platelet intracellular cal-
cium concentrations (Online Supplementary Figure S5), a
comparative quantitative analysis of GDI was not feasi-
ble because of differences in the ability of each receptor
to generate a robust calcium response when exposed to
a high agonist concentration gradient (2 s infusion time).
However, a transient and immediate calcium “spike” of
progressively smaller amplitude was obtained for PAR1-
AP and ADP even with medium and low agonist gradi-
ents, whereas longer infusion times generated prolonged
calcium mobilization with a temporal shift in [Ca2+]max for
PAR4-AP and U46619. To examine whether this phe-
nomenon was a unique feature of platelets or whether it
could be generalized to other cell types, we character-
ized the effects of GDI on PAR1 signaling in epithelial
cells, revealing calcium transients similar to those
observed in platelets, with diminishing calcium mobi-
lization with increasing infusion times (Online
Supplementary Figure S6).
Gradient-dependent inhibition of G protein-coupled
receptor-signaling leads to different levels of 
refractoriness to subsequent stimulation
With the presence of a gradient-dependent mechanism
for platelet activation verified in the above experiments,
we asked to what extent the unresponsive state induced
by low agonist gradients made platelets refractory to
subsequent stimulation with high gradients of the same
agonist. To answer this question, we performed experi-
ments on platelets that had been rendered unresponsive
to Cagg added with the concentration gradient ΔCnres (here-
inafter called GDI-platelets). We defined Cres as the min-
imal concentration required to achieve aggregation as a
response to instantaneous (2 s infusion time) addition of
the same agonist in GDI-platelets (algorithm in Figure
3A). As shown in Figure 3B and Table 1, GDI-platelets
could be activated by immediate addition of Cagg x 2 for
PAR1-AP and Cagg x 1 for PAR4-AP, clearly demonstrating
that GDI did not render platelets refractory to subse-
quent stimulation with the same agonist. In contrast, for
ADP, GDI induced a state of  pronounced unresponsive-
ness to subsequent activation, as we were unable to
identify a concentration of ADP that could induce
platelet aggregation in GDI-platelets, even when reach-
ing concentrations exceeding 20 x Cagg, a result consistent
with previous findings.11,12 Additional experiments
shown in Online Supplementary Figure S7 demonstrate
that GDI is strictly agonist-specific, as the aggregatory
response to heterologous stimulation of GDI-platelets
with another agonist (e.g. PAR4, ADP or U46619 in the
case of PAR1-induced GDI) was identical to that of
untreated platelets.
Platelet activation via PAR1 and PAR4 is 
gradient-dependent and not concentration-dependent
To confirm that the determinant of the aggregatory
response to the instantaneous addition of Cres was the ago-
nist concentration gradient and not the final agonist con-
centration, we investigated whether adding Cres with the
gradient ΔCnres to GDI-platelets could elicit the same aggre-
gation response as adding Cres instantaneously (Figure 3C).
In these experiments, GDI-platelets were exposed to
either instantaneous or prolonged gradient infusion to
reach the final concentration Cres. In contrast to the 2 s
infusion, no aggregation was observed when adding Cres
with the ΔCnres gradient using the agonists for which ΔCnres
and Cres could be defined (PAR1-AP and PAR4-AP). These
results show that the platelet response to these agonists is
independent of the final agonist concentration but highly
dependent on the agonist concentration gradient.
Gradient-dependent inhibition is regulated by a cAMP-
dependent pathway
A comparison of total serine phosphorylation levels in
GDI-platelets with those of resting and activated platelets
for the agonists PAR1-AP, PAR4-AP and ADP (Online
Supplementary Figure S8) showed that GDI involves specif-
ic phosphorylation events which are not observed in
either resting or activated platelets. In further explorations
into the mechanisms involved in GDI, we used PAR1 as
the model receptor as it was the receptor most prominent-
ly affected by GDI in our study. Since receptor internaliza-
tion has been reported as a common mechanism of desen-
sitization for GPCR,17-20 we compared platelet PAR1 recep-
tor density in resting platelets and GDI-platelets using
A.S. Macwan et al.
1486 haematologica | 2019; 104(7)
flow cytometry. Receptor density was found to be
unchanged in GDI-platelets, indicating that receptor inter-
nalization is not a major feature of GDI (Online
Supplementary Figure S9). A role for clathrin-mediated
receptor endocytosis was also excluded, as GDI was unaf-
fected by pre-treatment with the dynamin inhibitor
Dynasore21 (Online Supplementary Figure S10). Western
blotting revealed a prominent phosphorylation of VASP at
serine 157 in GDI-platelets, which was not observed in
resting or activated platelets (Figure 4A,B). As PKA is
involved in mediating phosphorylation at S157,22 we
examined the effects of PKA inhibition on VASP phospho-
rylation and GDI as measured by aggregometry.
Inhibition of PKA by 30 μM H89, which inhibited VASP
phosphorylation by 10 nM but not 100 nM prostacyclin
(PGI2) (Online Supplementary Figure S3B), did not in itself
cause aggregation of platelets, nor did it affect aggregation
induced by rapid (2 s) addition of 30 μM PAR1-AP.
However, the effects of GDI on PAR1-induced platelet
aggregation were partially reversed (Figure 4C). This effect
was also reflected in a decreased level of VASP phospho-
rylation in PKA-inhibited GDI-platelets treated with
PAR1-AP (Figure 4A,B). Furthermore, western blotting
revealed markedly decreased AKT phosphorylation in
GDI-platelets in comparison with that in activated
platelets (Figure 4D).
As both PKA and VASP are components of the cAMP/
adenylyl cyclase pathway, we examined the roles of
adenylyl cyclase and cAMP in GDI. Pre-treatment of
platelets with low doses of PGI2 (concentrations 0.01, 0.1
and 1 nM) to increase adenylyl cyclase activity did not
affect aggregation induced by a 2 s infusion of 30 µM
PAR1-AP, but significantly and dose-dependently
enhanced GDI at the 80 s and 160 s infusion times (Figure
4E). Similarly, pre-incubation of platelets with the phos-
phodiesterase-3 inhibitor milrinone (3 μM) to inhibit
cAMP degradation had no effect on aggregation at the 2s
infusion time, and did not affect platelet aggregation
induced by CRP-XL, at either the 2 s or the 1,280 s infu-
sion time (Figure 4F). In contrast, significant potentiation
of GDI was observed for PAR1-AP, PAR4-AP and ADP,
with a similar trend for U46619, although the effect did
not reach significance using this agonist. Treatment with
epinephrine (0.1, 1 and 10 μM) to inhibit adenylyl cyclase
60 s before starting agonist infusion with PAR1-AP or
thrombin did not in itself cause any aggregation, but pro-
duced a significant dose-dependent inhibition of GDI
(Figure 4G,H). This effect was most prominent for throm-
bin, as 1 μM epinephrine was sufficient to block GDI
completely for all tested infusion times.
The role of the VASP/PKA pathway in cytoskeleton
remodeling has been described previously.23 Also, VASP
has been shown to interact with F-actin and regulation of
F-actin rearrangement is modulated by differential phos-
phorylation of VASP.24 we, therefore, assessed morpholog-
ical and cytoskeletal changes in platelets induced by GDI
using fluorescence microscopy with staining for the
cytoskeletal protein F-actin. Compared to resting and acti-
vated platelets, GDI-platelets displayed a preferential dis-
tribution of F-actin filaments near the cell membrane
(Figure 5A). To confirm this finding and obtain more
insights into the structural characteristics unique to GDI-
Gradient-dependent inhibition of GPCR
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Figure 3. Agonist-specific effects of gradient-dependent inhibition. (A) Algorithm for defining Cres, the minimal concentration required to induce aggregation in
platelets showing gradient-dependent inhibition (GDI). (B) GDI was induced by exposing platelets to Cagg with ΔCnres for the agonists ADP, PAR1-AP and PAR4-AP.
Platelets were then challenged with the same agonist by adding multiples of Cagg with an infusion time of 2 s. (C) To investigate whether the determinant of the aggre-
gation induced by adding PAR1-AP or PAR4-AP at the concentration Cres, as shown above in (B), was the increased agonist gradient or the final agonist concentration,
subsequent infusions of Cres, using either the 2 s high gradient (1) or the GDI gradient ΔCnres (2), were performed.
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Figure 4. Mechanistic characterization of gradient-dependent inhibition. (A) Western blotting was performed on resting platelets (RST: treated with a 320 s infusion
of saline), activated platelets (ACT: treated with a 2 s infusion of 30 μM PAR1-AP) or platelets showing gradient-dependent inhibition (GDI: treated with a 320 s infusion
of 30 μM PAR1-AP) with staining for VASP phosphorylation at Ser157 or total VASP. Experiments were performed with or without pre-treatment with a PKA inhibitor
(H89) or PGI2. (B) Quantitation of the signal intensity, with the PGI2-mediated phosphorylation signal set at 100%, n=3. (C) Effects of the PKA inhibitor H89 on platelet
aggregation induced by 30 μM PAR1-AP added at a 2 s or 320 s infusion time. (D) Levels of total and phosphorylated AKT (Ser 473) in resting, activated or GDI platelets
determined by western blotting. (E) Effect of pre-incubation with PGI2 (0.01, 0.1 and 1 nM) on aggregation induced by 30 μM PAR1-AP added with different infusion
times. (F) Effect of the phosphodiesterase-3 inhibitor milrinone (Mil; 3 μM) on maximal platelet aggregation induced by Cagg (30 μM PAR1-AP, 300 μM PAR4-AP, 5 μM
ADP, 2 μM U46619, 0.16 μg/mL CRP-XL) added with different infusion times compared to control (Ctr). (G,H) Effects of epinephrine (Epi; 0.1, 1 and 10 μM) on GDI for
the agonists PAR1-AP (G) and thrombin (H) at different infusion times presented as a log scale on the x-axis (GDI calculated as % inhibition of maximal aggregation
compared to that with the 2 s infusion time). For all the experiments, data represent mean ± standard deviation, n≥3. *P<0.05, **P<0.01 and ***P<0.001. 
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platelets, electron microscopy was also performed, con-
firming the peripheral orientation of the cytoskeleton in
GDI-platelets and additionally indicating that the glyco-
gen bodies were more dispersed in GDI-platelets than in
resting platelets in which they were mostly present in
clusters (Figure 5B).
Discussion
Under healthy conditions, platelet hemostatic activity is
confined to areas near an acute vessel injury. The intracel-
lular mechanisms responsible for this spatiotemporal reg-
ulation of platelet activation are incompletely understood.
By systematically characterizing gradient-dependent
effects on stimulatory GPCR signaling in platelets (Table
1), our study shows that GDI represents a previously
unknown mechanism for dynamic regulation of GPCR
signaling, adaptively modifying platelet pro-hemostatic
activity as a response to different spatiotemporal distribu-
tions of agonist concentrations. Additionally, we identify
significant differences in susceptibility to GDI among the
receptors mediating responses to thrombin, ADP and
thromboxane A2 (Table 1), a finding with potential conse-
quences for the physiological roles of these agonists in
vivo.
Although GDI and desensitization share many features
and probably represent partially overlapping phenomena,
there are important differences motivating a distinction
between the two concepts. Desensitization can generally
be defined as the attenuation of a response due to pro-
longed or repeated stimulation, whereas the more specific
term “homologous receptor desensitization” refers to
downregulation of signal transduction after prolonged or
repeated stimulation of a receptor with an agonist.25 These
definitions imply that desensitization induces a state of
Gradient-dependent inhibition of GPCR
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Figure 5. Actin rearrangement and subcellular differences in resting platelets, activated platelets and platelets showing gradient-dependent inhibition. (A,B)
Morphological and cytoskeletal differences in resting platelets, platelets activated by 30 μM PAR1-AP, and platelets showing gradient dependent inhibition (GDI) for 30
μM PAR1-AP were visualized by fluorescence microscopy (A) using AF546-Phalloidin staining of F-actin (scale bar represents 3 μm) and by electron microscopy (B). In
electron micrographs, glycogen bodies (GB), a-granules (AG) and dense granules (DG) are shown with arrows and peripheral microtubular loops in GDI-platelets are
shown with arrowheads, with a higher magnification in GDI-II. The scale bar in the images represents 1 μm except in GDI-II where it represents 0.5 μm.
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unresponsiveness to further homologous stimulation. In
contrast, in the case of PAR receptor stimulation, our find-
ings show that GDI is strictly gradient-dependent, as
platelet reactivity to instantaneous additions of agonists
was found to be unaffected by GDI in our study. One
important exception from this rule was observed for ADP,
as ADP-induced GDI rendered platelets unresponsive to
further stimulation in our experiments. This finding sug-
gests that desensitization is an important mechanism of
ADP-induced GDI, in agreement with previous findings
showing that desensitization of P2Y12 receptors occurs
rapidly enough to affect ADP signaling during the time-
scales relevant for this study.12 In contrast, desensitization
of PAR receptors has previously only been reported to
occur upon prolonged exposure (typically 10-60 min) to
subthreshold concentrations of agonists.17,26,27 This is con-
trasted by the rapid and dynamic effects of GDI on throm-
bin-induced platelet activation observed in our study, as
an infusion time of 80 s was sufficient to completely
inhibit platelet aggregation as a response to stimulation
with 1 U/mL thrombin. The finding that PAR1 is the
receptor most prominently affected by GDI is not surpris-
ing when considering that the unique enzymatic activa-
tion mechanism of the PAR receptors, where one throm-
bin molecule theoretically could activate a large number of
PAR receptors, puts high demands on balancing inhibitory
signaling machinery, most particularly in the case of a
high-affinity receptor such as PAR1, requiring only sub-
nanomolar concentrations of thrombin to effect signifi-
cant receptor cleavage over time.17,27,28
Whereas GPCR desensitization typically involves slow
cellular processes such as altered protein translation and
receptor internalization,17-20,29 we provide evidence against
internalization or decoupling as a primary cause of GDI.
Firstly, in accordance with previous results from our
group,26 PAR1 receptor density was found to be unaffected
in GDI-platelets (Online Supplementary Figure S9).
Secondly, inhibiting dynamin had no effect on GDI
(Online Supplementary Figure S10), excluding a role for
clathrin-mediated receptor endocytosis. As additional
lines of evidence supporting a conceptual distinction
between GDI and desensitization, we present multiple
observations strongly supporting a mechanistic link
between GDI and activation of cAMP-dependent signal-
ing (Figure 6). This link provides mechanistic insight into
how GDI can be abolished by stimulation with inhibitors
of adenylyl cyclase such as ADP or epinephrine, empha-
sizing the important role of these agonists in GPCR signal-
ing. The unexpected observation that inhibition of
paracrine signaling potentiates GDI lends further support
to our notion that GDI is mechanistically related to the
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Table 1. Summary of measures characterizing gradient-dependent inhibition
of G protein-coupled receptor-mediated platelet aggregation.
Agonist                                Cagg (µM)           ΔCnres (s)        t50 (s)                      Cres (μM)
PAR1-AP                                            30                         320                 151                      60
           + inhibitors*                        30                         160                  77                      ND
PAR4-AP                                           300                      1280                607                     300
           + inhibitors*                       300                        640                 322                     ND
ADP                                                                                640                 485                     NA
U46619†                                              2                         1280                ND                      2‡
CRP-XL                                          0.16§                     NA                  NA                      NA
Cagg: the minimal agonist concentrations required to induce strong aggregation (>65%) in all
tested samples (n≥5); ΔCnres: the highest agonist concentration gradient for which >75% of sam-
ples are unresponsive (maximal aggregation <25 %) to Cagg; t50: the shortest infusion time at
which ≥50% of the samples ceased to aggregate; Cres: the lowest agonist dose required to
induce strong activation (>65% aggregation) when added at an infusion time of 2 s in all sam-
ples (n>5) after rendering platelets unresponsive to Cagg added with the gradient ΔCnres. *For
PAR1 and PAR4, ΔCnres and t50 were also determined in the presence of P2Y1, P2Y12, and throm-
boxane synthesis inhibitors, shown here as ‘+ inhibitors’. †t50 was not determined since GDI was
not observed for TPa in all experiments. ‡The Cres measurement for U46619 was calculated
from experiments in which gradient dependent inhibition was observed. §μg/mL. NA: not appli-
cable; ND: not determined.
Figure 6. Gradient-triggered activation of the cAMP-dependent pathway controls signaling from stimulatory G protein-coupled receptors. Signaling pathways with
a net stimulatory effect on platelet activation are colored red and signaling pathways with a net inhibitory effect are colored blue. (A) In the presence of high agonist
concentration gradients, strong activation of multiple stimulatory pathways will produce Akt phosphorylation, which in itself results in inhibition of the cAMP depend-
ent pathway by stimulation of PDE3 activity.39 (B) In the presence of low agonist concentration gradients, gradient-dependent activation of the cAMP-dependent path-
way will counteract stimulatory signaling from G protein-coupled receptors (GPCR), resulting in a refractory state characterized by an absence of Akt phosphorylation
but prominent VASP phosphorylation and non-responsiveness to high concentrations of agonists. As proof of the involvement of the cAMP-dependent pathway in gra-
dient-dependent inhibition (GDI), we found that GDI was effectively shut off by inhibition of adenylyl cyclase with epinephrine, and partially reversed by inhibition of
PKA with H89, while GDI was potentiated by stimulation of the cAMP-dependent pathway with PGI2 or milrinone. 
A B
cAMP-dependent pathway, as ADP is known to decrease
cAMP levels via inhibition of adenylyl cyclase.30 Lastly,
GDI-platelets exhibited altered levels of total serine phos-
phorylation and altered cytoskeletal organization in com-
parison with resting and activated platelets, indicating that
GDI involves the activation of unique kinase-dependent
signaling pathways.
Our results may, at least in part, explain previous find-
ings of non-responsive, “exhausted”, platelets in different
situations characterized by excessive diffusion of soluble
platelet agonists, for example in cancer,31-34 sepsis,34 and
intensive care.35-37 However, the term “exhausted” does
not fit with the findings in this study, as GDI-platelets
retain the capacity to be activated by other agonists or by
higher agonist gradients. The concept of GDI could also
help to explain recent findings from in vivo experiments,
showing the presence of a remarkably stable thrombus
architecture encompassing a large shell of loosely
attached, P-selectin-negative platelets with little calcium
mobilization surrounding a highly activated cluster of
platelets in the core of the thrombus.4,10 GDI could be one
mechanism responsible for maintaining low-grade acti-
vation in platelets forming the thrombus shell, despite
the inevitable slow leakage of ADP, thromboxane A2 and
thrombin,38 eventually leading to agonist accumulation
outside the core (Figure 7A,B). In this context, it is inter-
esting to note the different effects of GDI on paracrine
signaling from ADP and thromboxane on the one hand
and signaling from the thrombin receptors PAR1 and
PAR4 on the other. Whereas GDI had incremental
inhibitory effects on paracrine stimulation over a large
range of gradients, resulting in progressively weaker
platelet activation, a bimodal effect distribution was
observed for PAR-mediated signaling, as platelet activa-
tion was effectively shut off when gradients decreased
below a certain threshold. These differential effects of
GDI could be instrumental for the formation of the core-
shell thrombus architecture, as GDI could result in abol-
ished thrombin signaling outside the thrombus core,
whereas the gradual effects of GDI on paracrine stimula-
tion would result in the intermediary platelet activation
state found in the thrombus shell. The observation that
the collagen activation pathway (represented by CRP-
XL) was unaffected by GDI in our study is noteworthy
in this context, as collagen is not a diffusible agonist but
remains attached to the damaged vessel wall upon injury.
Thus, blood exposure to collagen is inherently restricted
to the immediate vicinity of vessel damage, rendering
GDI physiologically irrelevant as a regulatory mecha-
nism.
While this study focused exclusively on the gradient-
dependent effects of single agonists on platelet activation,
platelets circulating near a vessel injury are exposed to
multiple stimulatory gradients, primarily including the
agonists ADP, thromboxane A2 and thrombin. Adding
another layer of complexity, these pro-hemostatic signal-
ing pathways are counter-balanced by inhibitory signals
released from intact endothelium such as PGI2 and nitric
oxide. Thrombin receptors are quite common in the
human body, especially on cells in circulation. The pres-
ence of GDI in epithelial cells suggests that this phenom-
enon may be exhibited by other cell types. 
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Figure 7. Proposed role of gradient-dependent inhibition in creating and maintaining the core-shell thrombus architecture. (A) As gradient-dependent inhibition
(GDI) potently inhibits thrombin-induced platelet activation over a narrow range of temporal concentration gradients, we propose that stimulatory signaling via the
PAR receptors will effectively be shut off outside the thrombus core. (B) In contrast, as GDI exhibits a gradual increase over a larger range of gradients for ADP and
thromboxane A2, paracrine signaling from these agonists will only be partially inhibited, resulting in an intermediary state of platelet activation in the thrombus shell.
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